Xspray Pharma: The Waiting Game Continues - Börskollen
Fall: Vinst 34503 SEK i 2 veckor: KUNSKAPS- LEDNING - Karl
Vilka ägarna är. Xspray Pharma is a credible, high-tech, innovative company in the pharmaceutical industry, that through a unique revolutionary technology improves life-saving treatments. They needed a rebranding, a new responsive website, and further applications. The ma… BRIEF-XSpray Pharma Gets New U.S. Patent For HyNap-Dasa. By Reuters Staff. 1 Min Read Køb Xspray Pharma AB (XSPRAY) aktien.
Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Xspray Pharma is a credible, high-tech, innovative company in the pharmaceutical industry, that through a unique revolutionary technology improves life-saving treatments. They needed a rebranding, a new responsive website, and further applications. The ma… Xspray Pharma https://news.cision.com/se/xspray/r/villkoren-for-xspray-pharmas-notering-pa-nasdaq-stockholm-har-nu-uppfyllts,c3069789 2021-04-09 Xspray Pharma publishes Interim report Q4, January – December 2020 . Regulatory press release 2021-02-17.
Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed Regulatory press release 2021-02-25 Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 Press release 2021-03-05 Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed XSPRAY PHARMA AB (PUBL) : News, information and stories for XSPRAY PHARMA AB (PUBL) | Nasdaq Stockholm: XSPRAY | Nasdaq Stockholm View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. When Xspray Pharma last reported its balance sheet in December 2020, it had zero debt and cash worth kr326m. Importantly, its cash burn was kr141m over the trailing twelve months. That means it had a cash runway of about 2.3 years as of December 2020.
Xspray Pharma: Encouraging News Flow Placera - Avanza
Bid Price, Offer Price. High Price, Low Price, Open Price. Shares Traded, Last Xspray Pharma Ab (publ) (0GHZ) 1 Month Share Price History Xspray Pharma Ab (publ) Share Chat · Xspray Pharma Ab (publ) News · Xspray Pharma Ab $A2H48J #XSpray Pharma AB 1 director bought: A director at Xspray Pharma Ab bought 4,500 shares at 68.823SEK and the significance rating of the trade was Köp aktien Xspray Pharma AB (XSPRAY). Hos Nordnet 2021/01/04 Following these news, we raise our Base case to SEK220 (200) per share.
Press Release Distribution and Management - GlobeNewswire
High Price, Low Price, Open Price.
Since its cash burn is moving in the wrong direction, Xspray Pharma shareholders may wish to think ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has mandated Citigroup Global Markets Limited, Pareto Securities AB and Zonda Partners to evaluate the conditions for a directed share issue of approximately 1.9 million shares (the “Issue”), to institutional investors through an accelerated bookbuild transaction (“ABB”). Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue')..
Uppsala universitet nationalekonomi
Kan man visa detta registrerar man via ANDA och produkten kallas då generika. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter.
New recommendations for CML therapy. Imatinib brand or generic, dasatinib, nilotinib, and bosutinib are all recommended as 1st line therapy.
Athena su se
hg wells
koalitionsregering finland
annika falkengren familj
nedsättning aktiekapital bokföring
Xbrane Biopharma AB XBRANE : STO Stock Price & News
Xspray Pharma is a biotechnology company. Recent News & Activity Operating Status Active; Last Funding Type Series A; Legal Name Xspray Pharma AB. Stockopedia rates XSpray Pharma AB (publ) as a Speculative Style Neutral .
Analyse technique Xspray Pharma - Investtech
Det här uppger Avanzas sajt Placera.nu och berättar att bland andra Tredje AP-fonden, Handelsbanken Fonder, Andra AP-fonden, Swedbank Robur Fonder, Fjärde AP-fonden och TIN Ny Teknik 2021-03-28 · View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. But as . Xspray Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions. This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data. 2021-04-08 · XSpray Pharma Registered News: This is the News-site for the company XSpray Pharma Registered on Markets Insider XSpray Pharma AB (publ),556649-3671 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för XSpray Pharma AB (publ) Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its product candidate, HyNap-Nilo, for the treatment of chronic myeloid leukemia (CML). Get the latest Xspray Pharma AB (XSPRAY.ST) stock news and headlines to help you in your trading and investment decisions.
Publicerad: 2021-02-17 (MFN) Valberedningen föreslår Anders Ekblom till ny ordförande i Xspray Pharma.